EGFR and non-small cell lung carcinoma: In summary, neoadjuvant sintilimab plus nab-PC demonstrates acceptable clinical feasibility and a tolerable safety profile in locally advanced EGFR-mutant NSCLC, including those with EGFR insertion and other uncommon subtypes.